Recent Research Analysts’ Ratings Updates for Phathom Pharmaceuticals (PHAT)

A number of research firms have changed their ratings and price targets for Phathom Pharmaceuticals (NASDAQ: PHAT):

• 7/31/2026 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by Craig Hallum. They now have a $20.00 price target on the stock.
• 7/31/2026 – Phathom Pharmaceuticals had its price target lowered by Guggenheim from $25.00 to $22.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $26.00 price target on the stock.
• 7/30/2026 – Phathom Pharmaceuticals had its price target lowered by Needham & Company LLC from $28.00 to $22.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Phathom Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/17/2026 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $26.00 price target on the stock.

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.